Clinical trials: Newly-diagnosed Cancers
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Breast Cancer, Breast Cancer and Rehabilitation
Cancer Patient Navigation and Readiness
This study evaluated whether Cancer Patient Navigation (CPN) services could improve readiness for the transition from breast cancer diagnosis to treatment.
- Conditions
- Breast Cancer, Breast Cancer and Rehabilitation, Transition Care, Breast Cancer - Female
- Trial name
- CPN Readiness (NCT07892157)
- Testing
- Cancer Patient Navigation Services
- Where
- Indonesia
- Volunteers
- 64 people
- Sponsor
- Universitas Muhammadiyah Semarang
Breast Cancer Females, Newly Diagnosed Breast Cancer
Trial to Evaluate an Educational Video Series for Women in Breast Cancer Treatment
Approximately 200 English- or Spanish-speaking women newly diagnosed with stage I-III breast cancer will be randomized to either receive access to an online sexual health video series or receive usual care.
- Trial name
- NCT07434817
- Testing
- Sexual Health Educational Video Series, Standard Care (in control arm)
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Colorado, Denver
Newly Diagnosed Triple-negative Breast Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer
This study is a multicenter, randomized controlled phase III clinical trial. The aim of this study is to observe the efficacy and safety of PD-1 inhibitors combined with capecitabine, PD-1 inhibitors alone, or capecitabine alone…
- Trial name
- CREATE (NCT07869628)
- Testing
- Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine
- Volunteers
- 852 people
- Sponsor
- Shandong Cancer Hospital and Institute
Newly Diagnosed Multiple Myeloma
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible.
- Trial name
- NCT04052880
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Larysa Sanchez
Newly Diagnosed Cancer Patients
Smoking Cessation Intervention for Cancer Patients
The purpose of this study is to see if we can find ways to improve the treatment of tobacco dependence in patients who have cancer or may have cancer.
- Trial name
- NCT00575718
- Testing
- Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Newly Diagnosed Glioblastoma
REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma.
- Conditions
- Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
- Trial name
- REMIND (NCT07831772)
- Testing
- Maintenance Radiotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in…
- Trial name
- OPAL (NCT07739017)
- Testing
- CT-179
- Where
- 2 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ivosidenib when given together with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that is newly diagnosed (previously untreated), has…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04250051
- Testing
- Cytarabine, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Newly Diagnosed, Treatment-naïve Prostate Cancer
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the…
- Trial name
- PSMA-VISION (NCT07474142)
- Testing
- Not provided
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
- Trial name
- iNUDGE (NCT05853887)
- Testing
- iNUDGE
- Where
- 6 sites in United States
- Volunteers
- 260 people
- Sponsor
- Charu Aggarwal
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
Purpose: This clinical trial is designed to evaluate the safety and effectiveness of Trastuzumab Deruxtecan for patients with HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer.
- Trial name
- NCT07126561
- Testing
- Trastuzumab Deruxtecan
- Volunteers
- 43 people
- Sponsor
- University of Chicago
Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer.
- Trial name
- NCT01266096
- Testing
- PET scan with 124I-cRGDY-PEG-dots
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood Cancer, Childhood Cancers
Examination of the Relationship Between Quality of Life and Caregiving Burden Among Caregivers of Pediatric Oncology Patients
Primary Aim The primary aim of this study is to determine the quality of life and caregiving burden levels of caregivers of pediatric oncology patients and to examine the relationship between these two variables.
- Conditions
- Childhood Cancer, Childhood Cancers, Caregiver Subjective Burden, Primary Caregivers of Children Newly Diagnosed With Cancer
- Trial name
- NCT07308301
- Testing
- Assessment of caregiver quality of life and burden
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Fatma Beyza Akdeniz
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Newly Diagnosed Oligometastatic Prostate Cancer
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy…
- Trial name
- NCT03298087
- Testing
- radical prostatectomy, stereotactic body radiotherapy, Leuprolide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development
Breast Cancer, Newly Diagnosed Breast Cancer
Circulating miRNAs.
To identify a panel of circulating miRNA markers which could help identify those breast cancer patients who are most likely to respond well to neoadjuvant and adjuvant chemotherapy, and indeed serve as an overall prognostic…
- Conditions
- Breast Cancer, Newly Diagnosed Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01722851
- Where
- 7 sites in Ireland
- Volunteers
- 255 people
- Sponsor
- Cancer Trials Ireland
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH